Open Access Repository

Bertilimumab (Cambridge Antibody Technology Group)


Downloads per month over past year

Ding, C, Li, J and Zhang, X 2004 , 'Bertilimumab (Cambridge Antibody Technology Group)' , Current Opinion in Investigational Drugs, vol. 5, no. 11 , pp. 1213-1219 .

[img] PDF
bertilimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type: Article
Authors/Creators:Ding, C and Li, J and Zhang, X
Journal or Publication Title: Current Opinion in Investigational Drugs
ISSN: 1472-4472
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page